Neurofibromatosis Type 2 Clinical Trial
Official title:
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
To determine the hearing response rate at 24 weeks after treatment with bevacizumab for symptomatic vestibular schwannomas (VS) in children and young adults with Neurofibromatosis Type 2 (NF 2).
Subjects will be treated with open-label bevacizumab 10 mg/kg every 2 weeks for 24 weeks (induction therapy). Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 or 24 will be taken off of protocol. At week 24, patients with a clinical response or stable disease (together comprising "clinical benefit") will transition to maintenance therapy with bevacizumab. During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance). Subjects will be allowed to increase their bevacizumab dose to 10 mg/kg every 2 weeks during maintenance therapy if they experience hearing decline during maintenance therapy (defined as decrease in word recognition score below the 95% critical difference compared with the word recognition score at baseline, Appendix A). Subjects will be taken off of study if their word recognition score does not remain within the 95% critical difference after receiving bevacizumab 10 mg/kg every 2 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05521048 -
Doxycycline in Cutaneous Schwannoma (NF2)
|
Phase 1/Phase 2 | |
| Completed |
NCT01207687 -
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
|
Phase 2 | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Completed |
NCT01880749 -
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
|
Early Phase 1 | |
| Recruiting |
NCT05130866 -
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04374305 -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
|
Phase 2 | |
| Completed |
NCT01125046 -
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
|
Phase 2 | |
| Completed |
NCT03210285 -
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
|
||
| Completed |
NCT02934256 -
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
| Terminated |
NCT01345136 -
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
|
Phase 2 | |
| Completed |
NCT02104323 -
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
| Completed |
NCT02246231 -
Effect of Implant Position on Magnetic Resonance Image Distortion
|
N/A | |
| Terminated |
NCT02282917 -
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
|
Early Phase 1 | |
| Completed |
NCT02129647 -
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
| No longer available |
NCT02589912 -
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
|